Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zenas Biopharma Inc (ZBIO)

Zenas Biopharma Inc (ZBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,058,550
  • Shares Outstanding, K 53,679
  • Annual Sales, $ 5,000 K
  • Annual Income, $ -156,990 K
  • EBIT $ -194 M
  • EBITDA $ -194 M
  • 60-Month Beta -1.50
  • Price/Sales 55.05
  • Price/Cash Flow N/A
  • Price/Book 3.89

Options Overview Details

View History
  • Implied Volatility 143.00% (+16.55%)
  • Historical Volatility 240.17%
  • IV Percentile 88%
  • IV Rank 58.83%
  • IV High 189.19% on 01/02/26
  • IV Low 77.01% on 11/12/25
  • Expected Move (DTE 16) 4.68 (22.63%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 564
  • Volume Avg (30-Day) 706
  • Put/Call OI Ratio 1.13
  • Today's Open Interest 5,355
  • Open Int (30-Day) 5,998
  • Expected Range 15.99 to 25.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.22
  • Number of Estimates 3
  • High Estimate -0.32
  • Low Estimate -2.06
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.50 +53.04%
on 01/05/26
22.70 -8.99%
on 01/29/26
-13.84 (-40.12%)
since 01/02/26
3-Month
13.50 +53.04%
on 01/05/26
44.60 -53.68%
on 12/24/25
-9.29 (-31.02%)
since 11/04/25
52-Week
6.11 +238.13%
on 04/09/25
44.60 -53.68%
on 12/24/25
+13.00 (+169.71%)
since 02/04/25

Most Recent Stories

More News
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 20.66 (+4.77%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised...

ZBIO : 20.66 (+4.77%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised...

ZBIO : 20.66 (+4.77%)
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 20.66 (+4.77%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised...

ZBIO : 20.66 (+4.77%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised...

ZBIO : 20.66 (+4.77%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised...

ZBIO : 20.66 (+4.77%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)

NEW YORK , Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders.  The investigation...

ZBIO : 20.66 (+4.77%)
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically...

ZBIO : 20.66 (+4.77%)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 20.66 (+4.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc'RIIb. Zenas BioPharma Inc. is based in WALTHAM,...

See More

Key Turning Points

3rd Resistance Point 23.53
2nd Resistance Point 22.91
1st Resistance Point 21.78
Last Price 20.66
1st Support Level 20.03
2nd Support Level 19.41
3rd Support Level 18.28

See More

52-Week High 44.60
Fibonacci 61.8% 29.90
Fibonacci 50% 25.35
Fibonacci 38.2% 20.81
Last Price 20.66
52-Week Low 6.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar